Novel Drug Lanifibranor Promising for NASH
Lanifibranor, a first-in-class pan-PPAR agonist, hits the primary and key secondary end points in a phase 2b trial of patients with noncirrhotic, highly active nonalcoholic steatohepatitis.
Source: medscape.com